Xilio Therapeutics is a biotech company that develops tumor-activated immuno-oncology therapies. Its programs include a checkpoint inhibitor and cytokine programs, with investigational drugs in Phase 1 clinical trials for patients with advanced solid tumors. The company was founded in 2016 and is based in Waltham, Massachusetts.